New option listings for July 22nd include SIXG ETF (SIXG). Option delistings effective July 22nd include Oncternal Therapeutics (ONCT), Neurogene Inc. (NGNE), Remark Holdings Inc (MARK), AEye Inc (LIDR), GT Biopharma (GTBP), First Republic Bank (FRCB), Defiance Next Gen Connectivity ETF (FIVG), Evaxion Biotech (EVAX), Eiger Biopharmaceuticals Inc (EIGRQ), Cyclo Therapeutics Inc. (CYTH), CareMax (CMAX), Bodisen Biotech, Inc. (BODI), Biokey International (BKYI), comScore (SCOR), Safeguard Scientifics Inc (SFES), Sino-Global Shipping America (SGLY), TFF Pharmaceuticals (TFFP), and Instill Bio (TIL).
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ONCT:
- Oncternal completes enrollment, dosing in Phase 1/2 study of ONCT-534
- Oncternal Therapeutics to Present in JonesTrading Healthcare Summit
- Oncternal: Enrollment complete in 1/2 Study of ONCT-534 to treat R/R PCa
- Oncternal Announces Enrollment Completed and Dosing Initiated for Fifth Dose Cohort of Phase 1/2 Study of ONCT-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate Cancer
Questions or Comments about the article? Write to editor@tipranks.com